Oncology · GI toxicity in solid-tumour therapy
What is happening with NBL-101 right now?
Synthetic demo data
Active patients
600
Strong responders
188 / 31%
At-risk patients
180
Intervention opportunities
65
match trajectories that benefited from GI-04
Predicted discontinuations / 30 d
126
Emerging clusters
3
Predicted vs observed
Baseline model expectation against what the trajectories actually did.
| Metric | Predicted | Observed |
|---|---|---|
| Response | 52% | 61% |
| Severe GI toxicity | 18% | 15% |
| Discontinuation | 24% | 21% |
| Treatment persistence | 66% | 70% |
LIFE OS learned this week
All insightsA new treatment-response phenotype emerged
184 patients demonstrate early response followed by tolerance deterioration. LIFE OS flags the pattern around day 24; clinical recognition has typically come at day 61.
65 patients could benefit from intervention
Their trajectories currently resemble previous GI-04 responders. Among comparable trajectories, GI-04 reduced symptom burden by 20% and 72% improved.
State S14 predicts discontinuation
Patients entering treatment in state S14 are 3× more likely to reach high discontinuation risk than the program average (155 patients).
Unexpected strong responders
32 patients previously classified as moderate responders now show sustained response despite an early toxicity episode.